Filter by: patients
Home > Community Treatment Reports and Side Effects > Campral Treatment Report
What is Campral?

Campral is a brand name for the drug acamprosate used in the maintenance of alcohol abstinence.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Other 2 1 Efficacy_major
Ringing in ears (tinnitus) 1 1 Efficacy_none
Tardive dyskinesia 1 0
Alcohol addiction 1 0

See all 2 patients currently taking Campral

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 0
Moderate
 0
Mild
 0
None
 2

Commonly reported side effects, conditions, and hospitalizations associated with Campral

Diarrhea 1

Reported Dosages

  999 mg daily 1,998 mg daily
  1 Number of Patients: 1 1 Number of Patients: 1  

Reported Stop Reasons

Why Patients Stopped Taking Campral (multiple reasons could be selected)
Reason # Patients Percentage of patients
Did not seem to work 1   Did not seem to work: 33%
Expense 1   Expense: 33%
Course of treatment ended 1   Course of treatment ended: 33%

See all 3 patients who’ve stopped taking Campral

Reported Duration See details about how long patients take this treatment ▼

Currently Taking Campral

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Stopped Taking Campral

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of Campral

Always
 2 100%
Usually
 0 0%
Sometimes
 0 0%
Never
 0 0%

Burden

Difficulty being on treatment

Burden of Campral

Very
 0 0%
Somewhat
 0 0%
A little
 0 0%
Not at all
 2 100%

Cost

Paid out of pocket

Cost of Campral

$200+
 0 0%
$100-199
 1 50%
$50-99
 0 0%
$25-49
 1 50%
< $25
 0 0%

See more information, including instructions, precautions, side effects, and interactions.

Report created on May 25, 2012.